Kura Oncology (NASDAQ:KURA) Price Target Cut to $10.00 by Analysts at Scotiabank

Kura Oncology (NASDAQ:KURA) had its price target reduced by stock analysts at Scotiabank from $18.00 to $10.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “sector perform” rating on the stock. Scotiabank’s target price suggests a potential upside of 22.40% from the stock’s previous close.

KURA has been the topic of a number of other reports. Wedbush reaffirmed an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research report on Monday, November 4th. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. JMP Securities reiterated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Tuesday, November 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. Finally, UBS Group started coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.38.

Kura Oncology Stock Down 4.0 %

KURA stock opened at $8.17 on Wednesday. The stock’s 50 day simple moving average is $12.11 and its 200 day simple moving average is $17.08. The company has a market cap of $635.33 million, a P/E ratio of -3.46 and a beta of 0.81. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a fifty-two week low of $8.13 and a fifty-two week high of $24.17.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in KURA. nVerses Capital LLC bought a new position in shares of Kura Oncology in the third quarter valued at approximately $25,000. The Manufacturers Life Insurance Company boosted its position in Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after purchasing an additional 1,976 shares during the last quarter. Hsbc Holdings PLC grew its stake in Kura Oncology by 13.4% in the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after purchasing an additional 2,167 shares during the period. JPMorgan Chase & Co. increased its position in shares of Kura Oncology by 0.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares during the last quarter. Finally, Bellevue Group AG raised its stake in shares of Kura Oncology by 36.0% during the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after purchasing an additional 3,600 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.